Integrative Analysis of EPHX4 as a Novel Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26115095 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Pengze Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Jinan University, Guangzhou 510632, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Epoxide Hydrolases, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Postdoctoral Fellowship Program of China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, necessitating the identification of novel biomarkers for improved prognosis and diagnosis. This study investigates the role of epoxide hydrolase 4 (EPHX4), a member of the epoxide hydrolase family, in LUAD. Using data sourced from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, which were subsequently validated by the Gene Expression Omnibus (GEO), we analyzed levels of EPHX4 expression, mutation, and methylation in tumors versus normal tissues. Our findings revealed a significant upregulation of EPHX4 in LUAD tissues compared to normal lung tissues (p < 0.001), correlating with poorer overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). Furthermore, EPHX4 exhibited considerable diagnostic potential, as demonstrated by an area under the curve (AUC) of 0.854 in a Receiver Operating Characteristic (ROC) analysis. Notably, EPHX4 expression was associated with immune infiltration, specifically Th2 cells, neutrophils, and macrophages, along with immune checkpoint molecules including PD-L1, PD-L2, and TIM-3. Additionally, EPHX4 was involved in pivotal tumor-associated pathways, particularly cell cycle regulation. In conclusion, an elevated EPHX4 expression is indicative of poorer prognosis in LUAD and may play a role in immune evasion and cell cycle dysregulation, highlighting its potential as a promising biomarker for the diagnosis and prognostic prediction of LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine, Jinan University, Guangzhou 510632, China.
- School of Medicine, Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen 518107, China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Postdoctoral Fellowship Program of China Postdoctoral Science Foundation
Zitieren
APA
Liu, P., & Chen, Y. (2025). Integrative Analysis of EPHX4 as a Novel Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115095
Vancouver
Liu P, Chen Y. Integrative Analysis of EPHX4 as a Novel Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115095
BibTeX
@article{Liu2025,
author = {Liu, Pengze and Chen, Yutong},
title = {Integrative Analysis of EPHX4 as a Novel Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26115095}
}
EUVIMED